Search results for "rape"

showing 10 items of 2178 documents

Rosmarinic Acid Activates AMPK to Inhibit Metastasis of Colorectal Cancer

2018

Rosmarinic acid (RA) has been used as an anti-inflammatory, anti-diabetic, and anti-cancer agent. Although RA has also been shown to exert an anti-metastatic effect, the mechanism of this effect has not been reported to be associated with AMP-activated protein kinase (AMPK). The aim of this study was to elucidate whether RA could inhibit the metastatic properties of colorectal cancer (CRC) cells via the phosphorylation of AMPK. RA inhibited the proliferation of CRC cells through the induction of cell cycle arrest and apoptosis. In several metastatic phenotypes of CRC cells, RA regulated epithelial–mesenchymal transition (EMT) through the upregulation of an epithelial marker, E-cadherin, and…

0301 basic medicineAMPKrosmarinic acidCell cycle checkpointmatrix metalloproteinaseVimentincolorectal cancerMetastasis03 medical and health sciences0302 clinical medicineDownregulation and upregulationmedicinemetastasisPharmacology (medical)Protein kinase AOriginal ResearchPharmacologybiologyChemistryCell adhesion moleculelcsh:RM1-950EMTAMPKmedicine.disease030104 developmental biologylcsh:Therapeutics. PharmacologyApoptosis030220 oncology & carcinogenesisCancer researchbiology.proteinFrontiers in Pharmacology
researchProduct

Repurposing of Bromocriptine for Cancer Therapy

2018

Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug is also active against pituitary hormone-dependent tumors (prolactinomas and growth-hormone producing adenomas). We investigated, whether bromocriptine also inhibits hormone-independent and multidrug-resistant (MDR) tumors. We found that bromocriptine was cytotoxic towards drug-sensitive CCRF-CEM, multidrug-resistant CEM/ADR5000 leukemic cells as well as wild-type or multidrug-resistant ABCB5-transfected HEK293 cell lines, but not sensitive or BCRP-transfected multidrug-resistant MDA-MB-231 brea…

0301 basic medicineAbcg2DNA damageDNA repairCellneoplasmsergot alkaloids03 medical and health sciencesDopamine receptor D2AcromegalymedicinePharmacology (medical)Original ResearchbromocriptinepharmacogenomicsPharmacologydrug repurposingbiologybusiness.industrylcsh:RM1-950medicine.diseaseBromocriptinelcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structureMitochondrial respiratory chainCancer researchbiology.proteinbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Molecular Determinants of Sensitivity or Resistance of Cancer Cells Toward Sanguinarine.

2018

For decades, natural products represented a significant source of diverse and unique bioactive lead compounds in drug discovery field. In Clinical oncology, complete tumors remission is hampered by the development of drug-resistance. Therefore, development of cytotoxic agents that may overcome drug resistance is urgently needed. Here, the natural benzophenanthridine alkaloid sanguinarine has been studied for its cytotoxic activity against multidrug resistance (MDR) cancer cells. We investigated the role of the ATP-binding cassette (ABC) transporters BCRP/ABCG2, P-glycoprotein/ABCB1 and its close relative ABCB5 in drug resistance. Further drug resistance mechanisms analyzed in this study wer…

0301 basic medicineAbcg2Drug resistance03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCytotoxic T cellcancerPharmacology (medical)SanguinarineEpidermal growth factor receptorOriginal ResearchPharmacologypharmacogenomicsdrug resistancebiologyChemistrylcsh:RM1-950ABCB5phytotherapybioinformaticsMultiple drug resistancelcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinmicroarrayFrontiers in pharmacology
researchProduct

Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology

2018

Arsenic trioxide is a traditional remedy in Chinese Medicine since ages. Nowadays, it is clinically used to treat acute promyelocytic leukemia (APL) by targeting PML/RARA. However, the drug’s activity is broader and the mechanisms of action in other tumor types remain unclear. In this study, we investigated molecular modes of action by classical and network pharmacological approaches. CEM/ADR5000 resistance leukemic cells were similar sensitive to As2O3 as their wild-type counterpart CCRF-CEM (resistance ratio: 1.88). Drug-resistant U87.MG ΔEGFR glioblastoma cells harboring mutated epidermal growth factor receptor were even more sensitive (collateral sensitive) than wild-type U87.MG cells (…

0301 basic medicineAcute promyelocytic leukemiaBiologyNF-κB03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicinePharmacology (medical)Epidermal growth factor receptorArsenic trioxideTranscription factorOriginal ResearchpharmacogenomicsPharmacologydrug resistancelcsh:RM1-950PromoterAP-1medicine.diseasearsenic trioxidelcsh:Therapeutics. Pharmacology030104 developmental biologychemistryCistromeCell culture030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinFrontiers in Pharmacology
researchProduct

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

Re-examining the relationship between active cytomegalovirus (CMV) infection and acute graft-versus-host disease in allogeneic stem cell transplant r…

2015

0301 basic medicineAdultGraft RejectionMaleAdolescentmedicine.medical_treatment030106 microbiologyCongenital cytomegalovirus infectionCytomegalovirusGraft vs Host DiseaseHematopoietic stem cell transplantationTherapeuticsReal-Time Polymerase Chain ReactionCohort Studies03 medical and health sciencesYoung AdultAcute graft versus host diseasemedicineHumansTransplantation HomologousYoung adultAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalFollow up studiesHematopoietic Stem Cell TransplantationMiddle Agedmedicine.diseaseTransplantationReal-time polymerase chain reactionHematologic NeoplasmsImmunologyCytomegalovirus InfectionsFemaleStem cellbusinessFollow-Up StudiesTransplant international : official journal of the European Society for Organ Transplantation
researchProduct

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

2019

Abstract Aims Most clinical trials exclude elderly people, leading to a limited understanding of the benefit-to-risk ratio in this population. Despite existing data regarding the oncological management of elderly receiving fluorouracil (5-FU)-based regimen, our objective was to investigate 5-FU exposure/toxicity relationship in patients ≥75 years and compare the effectiveness of 5-FU therapeutic drug monitoring between elderly and younger patients. Methods Hundred fifty-four patients (31 of whom are older than 75 years) with gastrointestinal cancers, who were to receive 5-FU–based regimens, were included in our study. At cycle 1 (C1), the 5-FU dose was calculated using patient's body surfac…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationAntineoplastic Agents03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGastrointestinal cancereducationAgedGastrointestinal NeoplasmsRetrospective StudiesBody surface areaAged 80 and overeducation.field_of_studymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryArea under the curveMiddle Agedmedicine.disease3. Good healthClinical trialRegimen030104 developmental biologyOncologyTolerabilityTherapeutic drug monitoring030220 oncology & carcinogenesisFemaleFluorouracilDrug MonitoringbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Effect of ABC transporter expression and mutational status on survival rates of cancer patients

2020

ATP-binding cassette (ABC) transporters mediate multidrug resistance in cancer. In contrast to DNA single nucleotide polymorphisms in normal tissues, the role of mutations in tumors is unknown. Furthermore, the significance of their expression for prediction of chemoresistance and survival prognosis is still under debate. We investigated 18 tumors by RNA-sequencing. The mutation rate varied from 27,507 to 300885. In ABCB1, three hotspots with novel mutations were in transmembrane domains 3, 8, and 9. We also mined the cBioPortal database with 11,814 patients from 23 different tumor entities. We performed Kaplan-Meier survival analyses to investigate the effect of ABC transporter expression …

0301 basic medicineAdultMaleMutation rateNonsense mutationSingle-nucleotide polymorphismATP-binding cassette transporterRM1-950BiologyMultidrug resistanceP-glycoproteinPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNeoplasmsmedicineMissense mutationHumansSurvival analysisAgedCancerPharmacologyAged 80 and overPrognostic factorSequence Analysis RNACancerABCB5General MedicineMiddle AgedSurvival analysismedicine.diseaseMolecular Docking SimulationSurvival Rate030104 developmental biologyABC transporters030220 oncology & carcinogenesisMutationCancer researchATP-Binding Cassette TransportersFemaleTherapeutics. PharmacologyBiomedicine & Pharmacotherapy
researchProduct

Adult rat myelin enhances axonal outgrowth from neural stem cells.

2018

Axon regeneration after spinal cord injury (SCI) is attenuated by growth inhibitory molecules associated with myelin. We report that rat myelin stimulated the growth of axons emerging from rat neural progenitor cells (NPCs) transplanted into sites of SCI in adult rat recipients. When plated on a myelin substrate, neurite outgrowth from rat NPCs and from human induced pluripotent stem cell (iPSC)-derived neural stem cells (NSCs) was enhanced threefold. In vivo, rat NPCs and human iPSC-derived NSCs extended greater numbers of axons through adult central nervous system white matter than through gray matter and preferentially associated with rat host myelin. Mechanistic investigations excluded …

0301 basic medicineAgingNeuronalNudeMessengerNeurodegenerativeInbred C57BLRegenerative MedicineMedical and Health SciencesMyelinMiceNeural Stem CellsStem Cell Research - Nonembryonic - HumanCyclic AMPAxonPhosphorylationGray MatterInduced pluripotent stem cellExtracellular Signal-Regulated MAP KinasesSpinal Cord InjuryMyelin SheathInbred F344Neuronal growth regulator 1Stem Cell Research - Induced Pluripotent Stem Cell - HumanChemistryGeneral MedicineBiological SciencesWhite MatterNeural stem cellCell biologymedicine.anatomical_structureSpinal Cord5.1 PharmaceuticalsNeurologicalFemaleStem Cell Research - Nonembryonic - Non-HumanDevelopment of treatments and therapeutic interventionsPhysical Injury - Accidents and Adverse EffectsNeuriteCell Adhesion Molecules NeuronalCentral nervous systemNeuronal OutgrowthArticleWhite matter03 medical and health sciencesRats NudemedicineAnimalsHumansRNA MessengerStem Cell Research - Embryonic - HumanTraumatic Head and Spine InjuryTransplantationStem Cell Research - Induced Pluripotent Stem CellNeurosciencesStem Cell ResearchRats Inbred F344AxonsRatsMice Inbred C57BL030104 developmental biologynervous systemChondroitin Sulfate ProteoglycansRNACell Adhesion Molecules
researchProduct

Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?

2021

16 p.-9 fig.-1 tab.

0301 basic medicineAgonistAllosteric modulatormedicine.drug_classAllosteric modulatoradenosine triphosphateAllosteric regulationPharmacologyleukocyte-endothelium interactionsProinflammatory cytokine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseasesAbacavirmedicinePharmacology (medical)Original ResearchPharmacologyApyraseLeukocyte-endothelium interactionsabacavirlcsh:RM1-950Purinergic receptorallosteric modulatorvirus diseasesAbacavircardiovascular diseasesCardiovascular diseaseslcsh:Therapeutics. Pharmacology030104 developmental biologychemistryP2X7 receptorAdenosine triphosphate030217 neurology & neurosurgeryAdenosine triphosphatemedicine.drugFrontiers in Pharmacology
researchProduct